MAPK Signalling Cascade: How Tigilanol Tiglate Engages Cellular Stress Response Pathways
A focused look at how tigilanol tiglate (EBC-46) engages the MAPK family — ERK, JNK, and p38 — to amplify localised stress signalling within tumour tissue during preclinical experiments.
The mitogen-activated protein kinase (MAPK) cascade is one of the central signalling axes that translates extracellular stimuli into transcriptional and proteostatic responses. Tigilanol tiglate (the active compound in blushwood berry extract, also designated EBC-46) is a protein kinase C (PKC) activator with documented downstream effects on multiple MAPK branches. Understanding which MAPK arms are engaged — and in what sequence — clarifies how a localised application of the molecule produces the necrotic and inflammatory tumour response described in published preclinical work.
Three branches, one cascade family
The classical MAPK family contains three principal effector branches. The extracellular-signal-regulated kinase (ERK1/2) branch typically integrates growth and proliferation cues and is activated by mitogens. The c-Jun N-terminal kinase (JNK) branch is preferentially activated by cellular stress, cytokines, and DNA damage. The p38 MAPK branch responds to inflammatory stimuli, osmotic shock, and pathogen-associated molecules. All three are scaffolded through a tiered MAP3K → MAP2K → MAPK kinase architecture, and PKC-delta — the principal isoform engaged by tigilanol tiglate — sits upstream of multiple MAP3K inputs.
PKC-delta as the upstream switch
Tigilanol tiglate binds the C1 regulatory domain of conventional and novel PKC isoforms in a manner functionally analogous to diacylglycerol (DAG), but with sustained occupancy that prolongs PKC activation. The novel isoform PKC-delta has been identified as the dominant target in tumour cells. Sustained PKC-delta activity phosphorylates several MAP3Ks — including MEKK1 and ASK1 — that feed into the JNK and p38 branches. QBiotics, the developer of pharmaceutical tigilanol tiglate, has published mechanism-of-action overviews consistent with this PKC-driven model.
Why JNK and p38 dominate the tigilanol tiglate response
In preclinical tumour models, the dominant MAPK signal observed after tigilanol tiglate exposure is sustained JNK and p38 activation, with relatively modest ERK1/2 engagement. This pattern is consistent with a stress-response phenotype rather than a proliferative one. Sustained JNK activation phosphorylates the AP-1 transcription factor complex and shifts cellular gene expression toward apoptosis-priming and inflammatory cytokine output. p38 activation in parallel drives release of pro-inflammatory mediators including TNF-alpha and IL-6, which contribute to the rapid local immune cell recruitment characterised in the published in vivo work.
Crosstalk with other cell-death pathways
MAPK signalling does not act in isolation. JNK activation cooperates with mitochondrial outer membrane permeabilisation (MOMP) and caspase activation to commit cells to apoptosis, while p38 contributes to immunogenic features of cell death by driving DAMP release. This connects to a broader picture in which tigilanol tiglate engages multiple, partly redundant cell-death pathways simultaneously — apoptotic, necroptotic, and immunogenic — producing the rapid tumour disintegration documented in the QBiotics preclinical programme. Boyle et al. (2014, PLOS ONE) provided the foundational mechanistic characterisation that subsequent MAPK-focused studies have built on.
Why this matters for supplement-form research
Importantly, the MAPK characterisation summarised here was performed in cell-culture and intratumoural-injection models using pharmaceutical-grade tigilanol tiglate, not oral supplements. Oral blushwood berry extract — sold as a dietary supplement under DSHEA in the United States and equivalent frameworks elsewhere — has not been the subject of comparable mechanism-of-action work, and its pharmacokinetics differ from a localised injection. Brands such as Blushwood Health, which produce a 10:1 whole-seed blushwood berry extract, do not make pharmaceutical-grade or therapeutic claims for their products. The available mechanism literature is therefore a useful biological reference for understanding the molecule, not a guide to expected effects from supplement use.
References
2. QBiotics — Tigilanol Tiglate Mechanism Overview, 2026.
3. Davis RJ, "Signal Transduction by the JNK Group of MAP Kinases," Cell, 2000.
4. Blushwood Health — EBC-46 Supplement Information, 2026.
Related Articles
Immunogenic Cell Death and DAMPs: How EBC-46 Triggers Anti-Tumour Immunity
Caspase-Mediated Apoptosis: The Executioner Pathway in EBC-46 Cell Death
This article is for informational purposes only. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease.
